Search results
Showing 7516 to 7530 of 7707 results
Melanie explains how the update to our quality standard on the transition from children’s to adults’ services will benefit young people, their families and carers.
This International Women’s Day, we’re focusing on the invaluable contributions of 2 of the women who help shape our guidance through their independent voluntary committee roles. They talk to us about their involvement with NICE and what #InspireInclusion means to them.
New life-extending drug treatment for children and teenagers with an aggressive form of brain cancer
Dabrafenib with trametinib is a targeted treatment that can be taken at home rather than hospital and improves the length and quality of life for patients..
NICE recommends two CAR-T therapies, both given as one-off infusions, to treat aggressive forms of blood cancer.
Ovarian cancer patients to have NICE-approved drug combination option on Cancer Drugs Fund
A potentially life-extending drug combination for some people with advanced, high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer will now be available on the Cancer Drugs Fund (CDF), following its approval by NICE in draft guidance published today.
Over 700 people a year could benefit from a new lung cancer drug
An innovative and potentially life-extending drug for treating people with a specific gene mutation of advanced non-small-cell lung cancer (NSCLC) has been recommended by NICE and will be available to patients from today (Thursday, 14 April).
Over 500 people a year can access a new life extending lung cancer treatment
An innovative life-extending drug for treating mutation-positive locally advanced or metastatic non-small-cell lung cancer (NSCLC) in adults is being recommended by NICE as an option for use within the Cancer Drugs Fund.
Patients with rare blood disorders to receive new treatment option, says NICE
In final guidance published today (20 May 2021), NICE has recommended ravulizumab (Ultomiris, Alexion Pharmaceuticals) as a treatment for paroxysmal nocturnal haemoglobinuria (PNH). Draft guidance published 19 May 2021 also recommends the treatment for atypical haemolytic uraemic syndrome (aHUS).
Change in treatment for people with early breast cancer to benefit around 4,000
Around 4,000 people are set to benefit from a change in treatment for early breast cancer following provisional approval by NICE of abemaciclib in combination with hormone therapy.
NICE recommends Piqray and Trodelvy, maintaining 100% approvals of breast cancer drugs since 2018.
New tests could spare people with early breast cancer from unnecessary chemotherapy
More people with early breast cancer could be spared chemotherapy and therefore avoid the side effects associated with the treatment after tumour profiling tests were recommended by NICE.
Home testing devices could increase the number of people diagnosed with sleep apnoea
Five home-testing devices to diagnose a silent sleep condition harming the health of an estimated 2.5 million adults have been recommended by NICE in draft guidance.
25,000 people to benefit after NICE recommends new ulcerative colitis treatment
New one-a-day pill recommended on the same day the treatment was granted a licence by the MHRA.
145,000 people in England to have further treatment choice for preventing migraine attacks
NICE has for the first time recommended an oral treatment for preventing migraines.
Around 4,000 people with sickle cell disease could benefit from a new treatment recommended by NICE
Improved deal signals NICE recommendation of sickle cell treatment voxelotor.